ZGNX · Zogenix, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2015 |
|---|---|---|---|---|---|---|
| Revenue | $81.69M | $13.64M | $0 | - | $9.82M | $28.85M |
| Cost of Revenue | $4.83M | $542.0K | $10.73M | - | - | $0 |
| Gross Profit | $76.86M | $13.10M | ($10.73M) | - | - | $28.85M |
| R&D | $0 | $10.70M | $67.45M | $100.92M | $67.45M | $41.84M |
| SG&A | $148.52M | $99.57M | $60.79M | $38.95M | $25.89M | $27.00M |
| Total Operating Expenses | $305.79M | $261.36M | $129.76M | $141.18M | $129.76M | $101.53M |
| D&A | $9.46M | $5.46M | $1.27M | $155.0K | $425.0K | $1.40M |
| Operating Income | ($224.10M) | ($247.72M) | ($429.82M) | ($141.18M) | ($119.94M) | ($72.69M) |
| Interest Expense | - | - | - | - | - | $3.06M |
| Income Tax | $105.0K | ($17.43M) | $0 | $0 | $0 | ($948.0K) |
| Net Income | ($227.41M) | ($209.38M) | ($419.50M) | ($123.91M) | ($126.82M) | ($69.71M) |
| EPS - Basic | ($3.90) | - | - | - | ($4.65) | ($2.81) |
| EPS - Diluted | ($3.90) | - | - | - | ($4.65) | ($2.81) |
Balance Sheet
| Line item | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2015 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $101.18M | $166.92M | $62.07M | $68.45M | $293.50M | $91.55M |
| Accounts Receivable | $10.14M | $3.82M | - | - | $0 | $12.58M |
| Inventory | $5.49M | $1.03M | - | - | $0 | $7.05M |
| Accounts Payable | $22.00M | $11.95M | $7.98M | $7.99M | $3.36M | $4.55M |
| Current Assets | $354.57M | $522.17M | $287.24M | $532.73M | $304.70M | $119.91M |
| Total Assets | $468.49M | $651.13M | $414.25M | $648.33M | $417.61M | $231.50M |
| Current Liabilities | $97.69M | $82.72M | $95.39M | $58.38M | $20.98M | $20.31M |
| Long-term Debt | $158.16M | $0 | - | - | $0 | $18.82M |
| Total Liabilities | $289.52M | $281.46M | $169.19M | - | - | - |
| Stockholders' Equity | $178.97M | $369.67M | $245.06M | $522.80M | $301.52M | $120.76M |
| Retained Earnings | ($1.55B) | ($1.32B) | ($1.12B) | ($695.95M) | ($572.04M) | ($445.22M) |
Cash Flow
| Line item | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2015 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($185.31M) | ($167.53M) | ($111.52M) | ($111.66M) | ($75.87M) | ($72.88M) |
| Investing Cash Flow | $137.40M | ($165.10M) | $73.12M | ($444.75M) | ($76.0K) | $9.90M |
| Financing Cash Flow | ($17.83M) | $437.48M | $32.01M | $331.36M | $277.90M | ($817.0K) |
| CapEx | $83.0K | $679.0K | $9.49M | $1.02M | $76.0K | $103.0K |
| Free Cash Flow | ($185.39M) | ($168.21M) | ($121.01M) | ($112.68M) | ($75.95M) | ($72.98M) |
Ratios
| Metric | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2015 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 94.1% | 96.0% | - | - | - | 100.0% |
| Operating margin | -274.3% | -1815.7% | - | - | -1221.2% | -251.9% |
| EBITDA margin | -262.8% | -1775.7% | - | - | -1216.9% | -247.1% |
| Net margin | -278.4% | -1534.7% | - | - | -1291.3% | -241.6% |
| Free cash flow margin | -226.9% | -1232.9% | - | - | -773.3% | -253.0% |
| FCF / Net income | 0.82 | 0.80 | 0.29 | 0.91 | 0.60 | 1.05 |
| R&D / Revenue | 0.0% | 78.4% | - | - | 686.8% | 145.0% |
| SG&A / Revenue | 181.8% | 729.9% | - | - | 263.6% | 93.6% |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -48.5% | -32.2% | -101.3% | -19.1% | -30.4% | -30.1% |
| Return on equity | -127.1% | -56.6% | -171.2% | -23.7% | -42.1% | -57.7% |
| Return on invested capital | -52.5% | -52.9% | - | - | -31.4% | -41.1% |
| Liquidity | ||||||
| Current ratio | 3.63 | 6.31 | 3.01 | 9.13 | 14.52 | 5.90 |
| Quick ratio | 3.57 | 6.30 | 3.01 | 9.13 | 14.52 | 5.56 |
| Cash ratio | 1.04 | 2.02 | 0.65 | 1.17 | 13.99 | 4.51 |
| Leverage | ||||||
| Debt / Equity | 0.88 | 0.00 | - | - | 0.00 | 0.16 |
| Debt / Assets | 0.34 | 0.00 | - | - | 0.00 | 0.08 |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | -23.8x |
| Equity multiplier | 2.62 | 1.76 | 1.69 | 1.24 | 1.39 | 1.92 |
| Liabilities / Assets | 0.62 | 0.43 | 0.41 | - | - | - |
| Efficiency | ||||||
| Asset turnover | 0.17 | 0.02 | 0.00 | - | 0.02 | 0.12 |
| Inventory turnover | 0.88 | 0.53 | - | - | - | 0.00 |
| Days sales outstanding | 45d | 102d | - | - | 0d | 159d |
| Days inventory outstanding | 415d | 691d | - | - | - | - |
| Days payable outstanding | 1661d | 8044d | 271d | - | - | - |
| Cash conversion cycle | -1201d | -7251d | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | 498.8% | - | - | - | - | -28.8% |
| Revenue CAGR (3y) | - | 11.6% | - | - | -37.7% | -13.3% |
| Revenue CAGR (5y) | - | -13.9% | - | - | -26.0% | - |
| Gross profit growth (YoY) | 486.6% | - | - | - | - | 16.7% |
| Operating income growth (YoY) | 9.5% | 42.4% | -204.5% | -17.7% | - | -262.7% |
| Net income growth (YoY) | -8.6% | 50.1% | -238.5% | 2.3% | - | - |
| EPS growth (YoY) | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | -10.2% | -39.0% | -7.4% | -48.4% | - | 9.8% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -51.6% | 50.8% | -53.1% | 73.4% | - | 118.4% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2021-12-31.
Geographic
$74.74M totalUS$65.68M · 87.9%
Europe$9.06M · 12.1%
Stability scores
Altman Z′
FY 2021 · bankruptcy risk
-3.47
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2021 · 9-point quality
2/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- ✗Long-term debt decreased
- ✗Current ratio improved
- -No share dilution
- ✗Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing ZOGENIX against the 5 most active filers in the same SIC group.